The FDA has approved different biomarkers for ICIs, such as PD-L1 expression in tumor cells, microsatellite instability (MSI), and Tumor Mutational Burden (TMB), referring to the totality of somatic mutations (single nucleotide polymorphisms (SNPs) and variations of copy number (CNVs)) per million bases. Here, CD274 is linked to neoplasm.